OTraces has developed a patented technology to enhance the accuracy of cancer detection and surveillance with a simple blood test, currently for prostate cancer and breast cancer. Going beyond the current liquid biopsy technology, OTraces' blood test s biomarker agnostic and utilizes ordinary ELISA instrumentation. It is the first test to achieve access to active proteins found in the tumor ...
By OTraces Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you